Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Cost of Revenue (2020 - 2025)

Historic Cost of Revenue for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to $36.0 million.

  • Maravai Lifesciences Holdings' Cost of Revenue fell 221.79% to $36.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.9 million, marking a year-over-year increase of 207.03%. This contributed to the annual value of $150.9 million for FY2024, which is 143.4% up from last year.
  • Maravai Lifesciences Holdings' Cost of Revenue amounted to $36.0 million in Q3 2025, which was down 221.79% from $39.6 million recorded in Q2 2025.
  • Maravai Lifesciences Holdings' 5-year Cost of Revenue high stood at $53.3 million for Q4 2022, and its period low was $31.4 million during Q1 2021.
  • Its 5-year average for Cost of Revenue is $38.1 million, with a median of $37.8 million in 2021.
  • In the last 5 years, Maravai Lifesciences Holdings' Cost of Revenue skyrocketed by 10521.02% in 2021 and then crashed by 3407.32% in 2023.
  • Over the past 5 years, Maravai Lifesciences Holdings' Cost of Revenue (Quarter) stood at $39.1 million in 2021, then soared by 36.06% to $53.3 million in 2022, then tumbled by 34.07% to $35.1 million in 2023, then increased by 5.87% to $37.2 million in 2024, then dropped by 3.21% to $36.0 million in 2025.
  • Its last three reported values are $36.0 million in Q3 2025, $39.6 million for Q2 2025, and $39.1 million during Q1 2025.